DK88288D0 - Monoklonalt antistof, fremgangsmaade til fremstilling af samme og hybridcellelinie secernerende dettesamt celleoverflademarkoer, der udtrykkes paa human pankreascarcinomaceller - Google Patents

Monoklonalt antistof, fremgangsmaade til fremstilling af samme og hybridcellelinie secernerende dettesamt celleoverflademarkoer, der udtrykkes paa human pankreascarcinomaceller

Info

Publication number
DK88288D0
DK88288D0 DK088288A DK88288A DK88288D0 DK 88288 D0 DK88288 D0 DK 88288D0 DK 088288 A DK088288 A DK 088288A DK 88288 A DK88288 A DK 88288A DK 88288 D0 DK88288 D0 DK 88288D0
Authority
DK
Denmark
Prior art keywords
carcinom
markets
expressed
cells
preparing
Prior art date
Application number
DK088288A
Other languages
English (en)
Other versions
DK88288A (da
DK175546B1 (da
Inventor
Shama Kajiji
Vito Quaranta
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of DK88288D0 publication Critical patent/DK88288D0/da
Publication of DK88288A publication Critical patent/DK88288A/da
Application granted granted Critical
Publication of DK175546B1 publication Critical patent/DK175546B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK198800882A 1987-02-19 1988-02-19 Monoklonalt antistof, fremgangsmåde til fremstilling af samme, hybridomcellelinje og celleoverflademarkör samt peptider og komplekser heraf, og fremgangsmåder til påvisning/lokalisering af humant pancreascarcinom DK175546B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1655287A 1987-02-19 1987-02-19
US1655287 1987-02-19

Publications (3)

Publication Number Publication Date
DK88288D0 true DK88288D0 (da) 1988-02-19
DK88288A DK88288A (da) 1988-08-20
DK175546B1 DK175546B1 (da) 2004-12-06

Family

ID=21777714

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198800882A DK175546B1 (da) 1987-02-19 1988-02-19 Monoklonalt antistof, fremgangsmåde til fremstilling af samme, hybridomcellelinje og celleoverflademarkör samt peptider og komplekser heraf, og fremgangsmåder til påvisning/lokalisering af humant pancreascarcinom

Country Status (6)

Country Link
EP (1) EP0279669B1 (da)
JP (1) JP2792651B2 (da)
CA (1) CA1339709C (da)
DE (1) DE3854821T2 (da)
DK (1) DK175546B1 (da)
IL (1) IL85471A0 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310874A (en) * 1991-05-03 1994-05-10 The Scripps Research Institute Integrin α subunit cytoplasmic domain polypeptides and antibodies
EP0526888A3 (en) * 1991-08-06 1993-09-01 Toray Industries, Inc. Monoclonal antibody reactive with human pancreas cancer tissue
EP1411962B1 (en) * 2001-03-15 2011-01-19 Neogenix Oncology, Inc. Monoclonal antibody therapy for pancreas cancer
ATE419533T1 (de) 2002-10-31 2009-01-15 Hoffmann La Roche Verfahren/präparat zur erkennung von pankreaskrebs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3329184A1 (de) * 1983-08-12 1985-02-21 Behringwerke Ag, 3550 Marburg Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene
GR850552B (da) * 1984-03-07 1985-07-05 Du Pont

Also Published As

Publication number Publication date
EP0279669A2 (en) 1988-08-24
CA1339709C (en) 1998-03-10
DE3854821D1 (de) 1996-02-08
EP0279669A3 (en) 1989-09-27
DK88288A (da) 1988-08-20
JP2792651B2 (ja) 1998-09-03
IL85471A0 (en) 1988-07-31
JPS63301899A (ja) 1988-12-08
EP0279669B1 (en) 1995-12-27
DK175546B1 (da) 2004-12-06
DE3854821T2 (de) 1996-05-23

Similar Documents

Publication Publication Date Title
DK473887A (da) Hybridomacellelinie, monoklonalt antistof, fremgangsmaade til fremstilling af og anvendelse af det monoklonale antistof
IT8422580A0 (it) Composizioni che le contengono e proteine di membrana cellulare, procedimento per prepararle.
NO872217D0 (no) Konstruksjon omfattende parallelle plater med mellomliggende avstivningselement, samt fremgangsmaate til fremstilling av konstruksjonen.
DE69019009T2 (de) Zellkulturverfahren.
DE3876821T2 (de) Elektrolyt fuer eine elektrochemische festkoerperzelle.
DK509089A (da) Fremgangsmaade til dyrkning af mammale epidermale celler
DE3886356T2 (de) Indexgradientenlinsenanordnung in Gitterform.
DK537087D0 (da) Fremgangsmaade til modificering af lipid-strukturen i cellemembraner samt praeparat til anvendelse herved
DK478288D0 (da) Fremgangsmaade til fremstilling af phenolcelleplast med lukkede celler
DK85084D0 (da) Immunglobulin-producerende hybridcellelinier, deres anvendelse og fremgangsmade til deres fremstilling
DE3879766D1 (de) Halbleiter speicherzelle.
DK88288A (da) Monoklonalt antistof, fremgangsmaade til fremstilling af samme og hybridcellelinie secernerende dettesamt celleoverflademarkoer, der udtrykkes paa human pankreascarcinomaceller
FI891201A (fi) Elektrokemisk cell.
DK288388A (da) Fremgangsnmaade til udligning af sandsynligheden for afvisning i et celleinddelt mobilradiosystem
DK417483D0 (da) Cellevaekstmedium til brug in vitro
DE3672797D1 (de) Armierungseisenhalter zur verwendung bei anschlussbetonierungen.
FI880636A0 (fi) Foerfarande foer inaktivering av med hoelje foersedda virus i en medelst en cell in vitro framstaellda proteinprodukter.
DK382286A (da) Elektrokemisk celle og fremgangsmaade til fremstilling af samme
DK452786D0 (da) Hydrofilt materiale og fremgangsmaade til fremstilling af samme
DK319687A (da) Hybridcelle og fremgangsmaade til dens fremstilling ved fusion
DK673688A (da) Monoklone antistoffer, hybridom-cellelinier til f remstilling af antistofferne, fremgangsmaade til fremstilling af antistofferne og cellelinierne samt anvendelse af antistofferne
EP0274847A3 (en) A-associated h-antigens, monoclonal antibodies specific thereto and methods for employing the same in blood typing
DE3780855D1 (de) Zellkultur-methode.
DE3584629D1 (de) Spezifische karbohydratbindungsproteine (lektine) in saeugetiertumorzellen.
DK471487A (da) Braendselscelleelektrolytmatrice og fremgangsmaade til fremstilling af samme

Legal Events

Date Code Title Description
PBP Patent lapsed

Country of ref document: DK